When a pharmaceutical patent and FDA-granted exclusivity period expire, a competitor can, in principle, enter the market with a version of the same drug at a substantially lower price. For most of the twentieth century, no efficient regulatory pathway existed for such entry. The result was that brand-name drug prices held indefinitely, because full clinical trials were required to prove safety and efficacy anew even for drugs whose active ingredients were chemically identical to products already on the market. The Hatch-Waxman Act of 1984 changed that — but only for a subset of drugs. The biologics problem required a separate, later solution that has so far produced more limited results.
The Hatch-Waxman Act and the ANDA Pathway
The Drug Price Competition and Patent Term Restoration Act of 1984 — universally known as the Hatch-Waxman Act — established the Abbreviated New Drug Application (ANDA) pathway, allowing a manufacturer to seek FDA approval for a generic drug without repeating the costly clinical trials that established the original drug’s safety and efficacy. As the FDA’s 40th anniversary review of the law notes, when the Hatch-Waxman Amendments were enacted, only 19 percent of all prescription drug purchases in the U.S. were generics.
An ANDA applicant must demonstrate that its product contains the same active ingredient, in the same dosage form and strength, by the same route of administration, and is bioequivalent to the brand-name reference drug. Bioequivalence means the generic delivers the active ingredient at a rate and extent that does not differ significantly from the original. Because the FDA has already established that the active ingredient is safe and effective through the brand’s NDA, the generic manufacturer does not need to replicate that evidence — only to demonstrate it has made the same drug in a reliably equivalent way.
The law also created the Orange Book system for listing brand-name patents and established a “Paragraph IV” certification mechanism, under which a generic manufacturer can challenge listed patents as invalid or not infringed before the original patent expires. This created an adversarial but legally structured process for accelerating generic entry, with the first successful Paragraph IV challenger receiving 180 days of generic exclusivity as an incentive.
Why Generic Competition Reduces Prices
The mechanism by which generics reduce prices is straightforward: when multiple manufacturers can produce the same active ingredient, they compete on price. The cost structure of generic manufacturing is substantially lower than that of original drug development because the clinical evidence requirement is eliminated. Manufacturers without the original research and marketing costs can profitably sell at a fraction of the brand price.
The price effect tends to increase with the number of generic entrants. With a single generic, the brand price reduction may be modest — often 10 to 30 percent. With multiple generics, competition among them pushes prices substantially lower. Studies and FDA analyses consistently document reductions of 80 to 90 percent below the original brand price once a fully competitive generic market develops.
Biologics: A Different Category
For small-molecule drugs — conventional pills and tablets made through chemical synthesis — generic replication is chemically precise. The active ingredient of a generic aspirin or a generic metformin is, at the molecular level, identical to the brand-name product.
Biologics operate on different principles. They are large, complex molecules produced through living cell cultures — bacteria, yeast, or mammalian cells. The structure of a biologic is not solely determined by its gene sequence; it is also shaped by the manufacturing process itself, including cell line selection, growth conditions, purification steps, and formulation. Two manufacturers using the same DNA sequence but different cell lines will produce proteins that are highly similar but not molecularly identical. Minor variations in structure — differences in folding, glycosylation patterns, or other post-translational modifications — can affect how the drug behaves in the body.
This structural complexity has a regulatory consequence: no manufacturer can produce a biologic that is exactly the same as the reference product. A product that is “highly similar” to the reference biologic, with no clinically meaningful differences in safety, purity, or potency, is what the regulatory framework calls a biosimilar — not a generic.
The BPCIA and the Biosimilar Approval Pathway
Congress created the biosimilar approval pathway through the Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010. The BPCIA authorized the FDA to approve biosimilar products through an abbreviated pathway — similar in concept to the ANDA pathway, but with additional requirements reflecting the greater complexity of demonstrating biosimilarity.
A biosimilar applicant must demonstrate that its product is highly similar to the reference biologic using a totality-of-evidence approach, which typically involves extensive analytical characterization, animal studies, and clinical pharmacology data. The FDA may require clinical immunogenicity studies and, in some cases, efficacy trials — requirements that go substantially beyond what ANDA applicants face.
The BPCIA also established a 12-year exclusivity period for reference biologics — meaning the FDA may not approve a biosimilar application until 12 years after the reference product was first licensed. The FDA specifies that no biosimilar application can even be submitted until four years after licensure. This 12-year period significantly exceeds the five-year NCE exclusivity available for small-molecule drugs and is longer than biologic exclusivity periods in most other high-income countries.
The first U.S. biosimilar under the new pathway — filgrastim-sndz (Zarxio) — was approved in 2015, five years after the law was enacted.
Why Biosimilar Uptake Has Been Slower in the United States Than in Europe
Biosimilar frameworks existed in Europe before the BPCIA was enacted. The European Medicines Agency approved the first biosimilar in 2006. By the time the U.S. regulatory pathway was fully operational, European markets had years of practical experience with biosimilar adoption, formulary management, and price negotiation.
Comparisons of biosimilar uptake between the U.S. and Europe have consistently shown that European countries achieve higher market shares for biosimilars more quickly after their launch. A Duke-Margolis analysis found that U.S. uptake and use of biosimilars “have lagged greatly in comparison to Europe.” The gap reflects both the later start of the U.S. pathway and structural differences in the two markets.
Several U.S.-specific structural factors contribute to slower uptake:
First, the rebate contracting system in the United States creates incentives for pharmacy benefit managers (PBMs) and insurers to favor high-list-price brand biologics that offer large rebates, over lower-list-price biosimilars that offer smaller ones. A plan’s formulary position and net cost after rebates may favor the brand even when the biosimilar’s list price is lower.
Second, “interchangeability” — a designation the FDA can grant allowing pharmacists to substitute a biosimilar without physician intervention — requires additional clinical evidence demonstrating that switching back and forth between the reference product and the biosimilar produces no greater risk than using either product alone. Most biosimilars initially launched without interchangeability designation, limiting automatic pharmacy substitution.
Third, patient and physician familiarity with reference biologics, combined with manufacturer messaging emphasizing uncertainty about biosimilarity, has slowed clinical adoption in some therapeutic areas.
Manufacturer Strategies to Delay Biosimilar Competition
Manufacturers of reference biologics have deployed several documented strategies to delay or limit biosimilar competition beyond the statutory exclusivity period.
Pay-for-delay settlements: The FTC has documented arrangements in which brand-name manufacturers paid generic or biosimilar manufacturers substantial sums to settle patent litigation and delay market entry. The Supreme Court’s 2013 decision in FTC v. Actavis established that such reverse-payment settlements are subject to antitrust scrutiny, and the frequency of cash reverse payments declined substantially following that ruling. However, as a review in Pharmacy and Therapeutics{target=”_blank” rel=”noopener”} notes, some forms of non-cash reverse payments and other delay mechanisms persist.
Patent thickets: As documented in the patent and exclusivity article in this hub, manufacturers of biologics have filed extensive secondary patents on formulations, delivery devices, manufacturing processes, and methods of use. These patent thickets require biosimilar entrants to navigate complex litigation before market entry, and manufacturers can use the layered patent structure to extend practical exclusivity well past the 12-year regulatory period.
Rebate contracting arrangements: Manufacturers of reference biologics have offered pharmacy benefit managers and insurers contractual arrangements conditioning rebates on formulary exclusivity for the reference product. These arrangements can effectively foreclose biosimilar access to formularies even after FDA approval and regulatory exclusivity expiration. The FTC and academic researchers have examined these practices in the context of adalimumab (Humira), where the biosimilar entry in the U.S. was delayed to 2023 — seven years after biosimilars entered European markets.
“Patent dance” complexity under BPCIA: Unlike the Hatch-Waxman framework, the BPCIA’s patent dispute resolution process involves mandatory exchanges of patent information between the reference product manufacturer and the biosimilar applicant. This “patent dance” process is substantially more complex than the Paragraph IV process and has been criticized as adding time and legal cost to biosimilar development.
What the Research Shows About Price Effects
A 2018 RAND analysis estimated that biosimilars would reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, representing about 3 percent of total estimated biologic spending. That projection was based on assumptions about uptake that, in practice, have been more modest in the U.S. than in Europe.
For small-molecule drugs, the Hatch-Waxman framework has demonstrably delivered large-scale price reductions. Generics now account for roughly 90 percent of prescription drug dispensing in the United States by volume. The challenge is that the drugs driving the largest price concerns — biologics and specialty drugs — are precisely the ones for which the generic model does not apply and where the biosimilar pathway has delivered results more slowly than the small-molecule framework.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.